Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 16Terminated 6Withdrawn 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Lymphoid 1

Conditions

Pancreatic Neoplasms 2Lymphoma, T-Cell 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

Cyclophosphamide 35Cisplatin 24fludarabine 23Radiotherapy 23Paclitaxel 21Carboplatin 20pembrolizumab 18Nivolumab 18Magnetic Resonance Spectroscopy 18Specimen Handling 17fludarabine phosphate 15Gemcitabine 15Biopsy 15Cytarabine 14Radiation 11Filgrastim 11Doxorubicin 11Docetaxel 11Dexamethasone 11Radiosurgery 10Granulocyte Colony-Stimulating Factor 10Etoposide 10Melphalan 9Ipilimumab 9venetoclax 8Rituximab 8Calcium Dobesilate 8trametinib 7ibrutinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × entinostat × Clear all
NCT03760614 2021-01-15

A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma

Abramson Cancer Center at Penn Medicine

Phase 1 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT03925428 2020-09-28

Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas

National Cancer Institute (NCI)

Phase 1 Withdrawn
GastrointestinalLymphoid

Lymphoma, Pancreatic Neoplasms, Lymphoma, B-Cell, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡